| Literature DB >> 35461244 |
Colleen Hood1, Reza Zamani1, Mohammad Akrami2.
Abstract
BACKGROUND CONTEXT: Lumbar total disc replacement (TDR) is an alternative to lumbar fusion in the treatment of lower back pain and reduces the risk of adjacent segment degeneration. Heterotopic ossification (HO) has been identified as a common complication following lumbar TDR.Entities:
Keywords: Arthroplasty; Clinical outcome; Degenerative disc/disk; Disc/disk disease; Disc/disk replacement; Heterotopic ossification; Lumbar spine; Spine surgery; Systematic review
Mesh:
Year: 2022 PMID: 35461244 PMCID: PMC9034498 DOI: 10.1186/s12891-022-05322-9
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.562
Search term combination and total hits from the systematic search of MEDLINE, Scopus, PubMed and Cochrane Central databases
| Search combination and total hits | |
|---|---|
| Search Combination | Total Hits |
| “Heterotopic ossification” AND lumbar AND arthroplasty | 89 |
| “Heterotopic ossification” AND lumbar AND “disc replacement OR disk replacement” | 94 |
| “Heterotopic ossification” AND lumbar AND “disc OR disk” AND prosthesis | 80 |
| Heterotopic AND bone AND lumbar AND arthroplasty | 55 |
| Heterotopic AND bone AND lumbar AND “disc replacement OR disk replacement” | 47 |
| Heterotopic AND bone AND lumbar AND “disc OR disk” AND prosthesis | 44 |
| “Heterotopic ossification” AND lumbar AND “degenerative disc disease OR degenerative disk disease” | 54 |
| “Heterotopic ossification” AND lumbar AND “degenerative disc disease OR degenerative disk disease” | 24 |
Fig. 1PRISMA flow diagram
Study characteristics
| Ref | First Author | Study Location | Year of Publication | Journal | Study Design | Sample Size | Outcome Measure(s) | Mean Follow Up (years) |
|---|---|---|---|---|---|---|---|---|
| [ | G.Pokorny | Brasil | 2019 | World Neurosurgery | Non random, prospective | 60 | Heterotopic ossification rates, Pain VAS scores, ODI scores, reoperation rates | 7.75 |
| [ | F. Gornet | USA | 2019 | Journal of Neurological spine | RCT | 577 | Heterotopic ossification rates, Pain VAS scores, ODI scores, ROM, Reoperation rates | 5 |
| [ | H.Park | Korea | 2018 | The Spine Journal | Retrospective case review | 65 | Heterotopic ossification rates | 8.7 |
| [ | S.Lu | China | 2018 | The Spine Journal | Retrospective | 35 | Heterotopic ossification rates, Pain VAS scores, ODI scores | 15.2 |
| [ | V,A. Byvaltsev | Russia | 2017 | Coluna/Columna | Non random, prospective | 156 | Heterotopic ossification rates, Pain VAS scores, ODI scores, ROM | 3 |
| [ | A,G. Tohmeh | USA | 2015 | European Spine Journal | Non random, prospective | 64 | Heterotopic ossification rates, Pain VAS scores, ODI scores, Reoperation rates | 3 |
| [ | S. Lu | China | 2015 | European Spine Journal | Non random, prospective | 35 | Heterotopic ossification rates, Pain VAS scores, ODI scores, ROM, Reoperation rates | 11.8 |
| [ | S.Lu | China | 2015 | Journal of Spinal Disorders | Non random, prospective | 32 | Heterotopic ossification rates, Pain VAS scores, ODI scores, ROM, Reoperation rates | 2.4 |
| [ | J,R. Baldeston | USA | 2014 | Spine | Non random, prospective | 15 | Heterotopic ossification, ODI scores | 9.6 |
| [ | A,R. Meir | Australia | 2013 | The Spine Journal | Non random, prospective | 28 | Heterotopic ossification, Reoperation rates | 9.6 |
| [ | L. Marchi | Brazil | 2012 | International Journal of Spine Surgery | Non random, prospective | 36 | Heterotopic ossification rates, Pain VAS scores, ODI scores, Reoperation rates | 3 |
| [ | C. Jones | Australia | 2012 | Orthopaedic Surgery | Retrospective | 25 | Heterotopic ossification | 2.83 |
| [ | S. Park | Korea | 2011 | International Orthopaedics | Non random, Prospective | 65 | Heterotopic ossification | 3.75 |
| [ | G. Cinotti | Italy | 1996 | Spine | Non random, Prospective | 46 | Heterotopic ossification, Reoperation rates | 3.2 |
| [ | M. Putzier | Germany | 2006 | European Spine Journal | Retrospective | 71 | Heterotopic ossification, Reoperation rates | 17.3 |
| [ | R. Guyer | USA | 2016 | Spine | RCT | 394 | Heterotopic ossification rates, Pain VAS scores, ODI scores, ROM, Reoperation rates | 5 |
| [ | J, P. Lemaire | France | 2005 | Journal of Spinal Disorders | Non random, prospective | 107 | Heterotopic ossification | 11.3 |
| [ | R. Guyer | USA | 2009 | The Spine Journal | RCT | 133 | Heterotopic ossification rates, Pain VAS scores, ODI scores | 5 |
| [ | R. Garcia Jr | USA | 2015 | Spine | RCT | 324 | Heterotopic ossification rates, Pain VAS scores, ODI scores, Reoperation rates | 2 |
| [ | M. Katsimihas | Canada | 2010 | Canadian Journal of Surgery | Non random, prospective | 64 | Heterotopic ossification rates, Pain VAS scores, ODI scores, Reoperation rates | 4.58 |
| [ | J,C. Le Huec | France | 2005 | Orthopaedic Clinics of North America | Non random, prospective | 64 | Heterotopic ossification rates, Pain VAS scores, ODI scores | 2 |
| [ | A,V. Ooij | Netherlands | 2003 | Journal of Spinal Disorders | Retrospective | 27 | Heterotopic ossification | 7.58 |
| [ | E. Van De Kelft | Belgium | 2012 | World Neurosurgery | Non random, prospective | 50 | Heterotopic ossification rates, Pain VAS scores, ODI scores | 4 |
| [ | T. David | France | 2007 | Spine | Retrospective | 108 | Heterotopic ossification, Reoperation rates | 13.2 |
| [ | P. McAfee | USA | 2003 | Journal of Spinal Disorders and techniques | RCT | 60 | Heterotopic ossification | 3 |
| [ | R. Fraser | Australia | 2004 | The Spine Journal | Non random, prospective | 28 | Heterotopic ossification rates, ODI scores, Reoperation rates | 2 |
Fig. 2Risk of bias for randomised controlled trials summary figure
A summary of the methodological quality of the studies included in this systematic review
| Ref | Study design | Sample size | Drop Out /Withdrawal Rate | Scimago Journal rating | MINORS score (out of 16) |
|---|---|---|---|---|---|
| [ | Non randomised prospective single centre study | 60 | 9—no reasons given | Q2 | 10 |
| [ | RCT | 577 | 8 unrelated deaths, 146—no reasons given | Q1 | N/A |
| [ | Retrospective case review | 65 | 17—no reasons given | Q1 | N/A |
| [ | Retrospective single centre clinical trial | 35 | 5—no reasons given | Q1 | N/A |
| [ | Non randomised prospective multi centre study | 156 | N/A | Q4 | 8 |
| [ | Non randomised prospective multi centre clinical study | 64 | 4—no reasons given | Q1 | 11 |
| [ | Non randomised prospective clinical trial | 35 | 1 lost to follow up, 1 unrelated death, 1 declined participation | Q1 | 10 |
| [ | Non randomised prospective clinical trial | 32 | 2—no reasons given | N/A | 11 |
| [ | Non randmoized prospective clinical data analysis | 15 | 2 lost due to change in contact details | Q1 | 10 |
| [ | Non randomised prospective clinical trial | 28 | 2 lost due to change in contact details | Q1 | 9 |
| [ | Non randomised prospective single centre study | 36 | N/A | Q2 | 7 |
| [ | Retrospective study | 25 | 3—no reasons given | Q3 | N/A |
| [ | Non randomised Prospective study | 65 | N/A | Q1 | 6 |
| [ | Non randomised prospective study | 46 | N/A | Q1 | 6 |
| [ | Retrospective | 71 | 18—no reasons given | Q1 | N/A |
| [ | RCT | 394 | 124—no reasons given | Q1 | N/A |
| [ | Non randomised prospective study | 107 | 6 lost due to change in contact details, 1 unrelated death | N/A | 6 |
| [ | RCT | 133 | 11 declined participation, 10 early discontinuation and 96 no reasons given | Q1 | N/A |
| [ | RCT | 324 | 58—no reasons given | Q1 | N/A |
| [ | Non randomised prospective study | 64 | 7—no reasons given | Q2 | 11 |
| [ | Non randomised prospective study | 64 | No drop outs | Q1 | 10 |
| [ | Retrospective | 27 | N/A | N/A | N/A |
| [ | Non randomised prospective study | 50 | 5- lost due to change in contact details | Q2 | 9 |
| [ | Retrospective | 108 | 2-unrelated death | Q1 | N/A |
| [ | RCT | 60 | No drop outs | Q1 | N/A |
| [ | Non randomised prospective study | 28 | N/A | Q2 | 7 |
*MINORS Methodological Index for Non-Randomized Studies
Outcome measures
| Ref | HO at the surgical level | Patients with indications of HO at index level | Percentage of patients with HO | HO graded by McAfee or other scale? | Mean percentage change in visual analogue scores for perceived patient pain | Mean percentage change in Oswestry disability scores of patients | Mean percentage change in |
|---|---|---|---|---|---|---|---|
| [ | N/A | 41 | 91.1 | YES | 61.1 | 60.1 | N/A |
| [ | 11 | 11 | 5.88 | NO | 73.6 | 66.4 | 31.8 |
| [ | 30 | N/A | 50 | YES | N/A | N/A | N/A |
| [ | 26 | N/A | 74.3 | YES | 81.6 | 89.9 | N/A |
| [ | 37 | 37 | 23.7 | YES | 82.6 | 68.9 | 10.6 |
| [ | 3 | 3 | 5.36 | NO | 68.5 | 64.7 | N/A |
| [ | 25 | N/A | 71.4 | YES | 82.8 | 68.1 | -37 |
| [ | N/A | 1 | 3.33 | NO | 82.6 | 62.8 | 27.99 |
| [ | 0 | 0 | 0 | YES | N/A | 81.5 | N/A |
| [ | 12 | N/A | 85.7 | NO | N/A | N/A | N/A |
| [ | N/A | 7 | 20 | NO | 74.4 | 69.3 | N/A |
| [ | 19 | N/A | 83 | YES | N/A | N/A | N/A |
| [ | 25 | N/A | 30.5 | YES | N/A | N/A | N/A |
| [ | N/A | 7 | 15.2 | NO | N/A | N/A | N/A |
| [ | N/A | 39 | 73.6 | YES | N/A | N/A | N/A |
| [ | N/A | 32,36 | 15.9,19.3 | NO | 69.6, 71.8 | 63.7, 66.1 | 15.3 |
| [ | N/A | 3 | 3 | NO | N/A | N/A | N/A |
| [ | 17 | 17 | 18.9 | NO | 55.7 | 49.4 | N/A |
| [ | 3,1 | 3,1 | 1.6, 1.1 | NO | 74,68 | 67, 61 | N/A |
| [ | 0 | 0 | 0 | yes | 50 | 50 | N/A |
| [ | 3 | 3 | 4.69 | YES | 57.9 | 47.3 | N/A |
| [ | N/A | 4 | 14.2 | NO | N/A | N/A | N/A |
| [ | 0 | 0 | 0 | YES | 64.9 | 69.3 | N/A |
| [ | 7 | 7 | 6.6 | NO | N/A | N/A | N/A |
| [ | 1 | 1 | 2.22 | YES | N/A | N/A | N/A |
| [ | N/A | 1 | 3.56 | NO | N/A | 30.2 | N/A |
HO Heterotopic ossification, VAS Visual Analogue Scores for Perceived Pain, ODI Oswestry Disability Index, ROM Range Of Motion at index level
Patient demographics
| Surgical Level/Segment | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Male (%) | Mean Age | Device design | Smokers(%) | Surgery | L1-2 | L2-3 | L3-4 | L4-5 | L5-S1 |
| [ | 52% | 42.8 | XL-TDR | N/A | Lateral Approach | N/A | 3 | 10 | 42 | N/A |
| [ | 50% | 39.9 | Maverick | 28.9 | Anterior Approach | N/A | N/A | N/A | N/A | N/A |
| [ | 33% | 44.8 | ProDisc II (92%), Charite 8% | N/A | Anterior Approach | N/A | N/A | N/A | N/A | N/A |
| [ | 53% | 59.4 | Charite III | N/A | Anterior Approach | N/A | N/A | 1 | 18 | 6 |
| [ | N/A | N/A | M6-L | N/A | N/A | N/A | N/A | 10 | 43 | 103 |
| [ | 58% | 45.3 | XL-TDR | 20.3 | Lateral Approach | 2 | 3 | 11 | 48 | N/A |
| [ | 44% | 41.4 | Charite III | N/A | Anterior Approach | N/A | N/A | N/A | N/A | N/A |
| [ | 60% | 45.1 | Active L | N/A | Anterior Approach | N/A | N/A | 3 | 23 | 10 |
| [ | 31% | 44.3 | ProDisc L | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| [ | 50% | 41 | AcroFlex | 39.2 | Anterior RPA | N/A | N/A | N/A | N/A | N/A |
| [ | 44% | 42.6 | XL-TDR | N/A | Lateral Approach | N/A | N/A | 4 | 17 | N/A |
| [ | 48% | N/A | Charite III | N/A | Anterior Approach | 1 | 1 | 3 | 9 | 10 |
| [ | 37% | 43.8 | Prodisc (91%) and Charite (9%) | N/A | Anterior Approach | N/A | N/A | 3 | 46 | 33 |
| [ | 46% | 36 | Charite III | N/A | Anterior Approach | N/A | N/A | 4 | 26 | 30 |
| [ | 38% | 44 | Charite I (25%), II(40%), III(35%) | N/A | Anterior Approach | N/A | N/A | 2 | 35 | 26 |
| [ | 47% | 39.6, 39.9 | Kineflex (52%) Charite III (48%) Control | N/A | Anterior Approach | N/A | N/A | N/A | 46, 48 | 158, 142 |
| [ | 41% | 39.6 | Charite III | N/A | Anterior Approach | N/A | N/A | 6 | 69 | 72 |
| [ | 52% | 40 | ChariteIII (67%) AND BAk fusion (33%) | N/A | Anterior Approach | N/A | N/A | N/A | 26 | 64 |
| [ | 52% | 39,40 | Active L (67%), Prodisc OR charite (33%) | 39.2 | Anterior Approach | N/A | N/A | N/A | 62,34 | 156,72 |
| [ | 39% | 39 | Charite III | 61.4 | Anterior Approach | N/A | N/A | N/A | 4 | 53 |
| [ | 39% | 44 | Maverick | 29.7 | Anterior Approach | N/A | N/A | 2 | 27 | 35 |
| [ | 44% | 38 | Charite III | N/A | Anterior Approach | N/A | 1 | 2 | 19 | 11 |
| [ | 48% | 37.1 | Maverick | N/A | Anterior Approach | N/A | 1 | 2 | 19 | 28 |
| [ | 42% | 36.4 | Charite III | N/A | Anterior Approach | N/A | N/A | 1 | 25 | 82 |
| [ | 50% | 40.3 | Charite III (68%), BAK Fusion (32%) | N/A | Anterior Approach | N/A | N/A | N/A | 19 | 41 |
| [ | 50% | 41 | Acroflex | 39.2 | Anterior Approach | N/A | N/AA | N/A | 9 | 23 |
*N/A data not reported/unavailable
Fig. 3Scatter graph of HO rate and mean age
Fig. 4Scatter graph of HO rate and mean follow up